

*Forum on
Immunopathological Diseases and Therapeutics*

VOLUME 5 CONTENTS, 2014

PAGE RANGE OF ISSUES: Issues 1-2: 1-114; Issues 3-4: 115-241

Numbers 1-2

**NEW IMMUNOLOGICAL APPROACHES TO CANCER THERAPY DEDICATED TO DR. MICHIO NISHIDA
GUEST EDITOR: RONALD NEWMAN**

Rituxan: The First 20 Years	1
<i>R. Newman</i>	
CD20 and Its Antibodies: Past, Present, and Future	7
<i>R.J. Oldham, K.L.S. Cleary, & M.S. Cragg</i>	
The New Generation of Antibody Drug Conjugates	25
<i>V. Blot, R. Richardson, & J. Coronella</i>	
Adoptive Immunotherapy of Cancer Using Chimeric Antigen Receptor–Engineered T Cells	47
<i>D. Achkova & J. Maher</i>	
Checkpoint Modulators in Cancer Immunotherapy	69
<i>J.G. Sathish</i>	
Immunocytokines for Cancer Therapy	83
<i>P. Probst & D. Neri</i>	
Alternative Scaffolds as Therapeutics in Cancer and Other Diseases	101
<i>U. Wuellner & D. Grabulovski</i>	

Numbers 3-4

**ADVANCES IN MOLECULAR TARGETS FOR THERAPEUTICS IN RESISTANT CANCERS
GUEST EDITORS: MELCHIORRE CERVELLO & NATALE D'ALESSANDRO**

Epidemiology, Diagnosis, and Non-Pharmacological Treatment of HCC	115
<i>M. Soresi, L. Giannitrapani, W. Granà, A. Licata, & G. Montalto</i>	
The Role of HSP70 in the Diagnosis of HCC	137
<i>L. Giannitrapani & G. Multhoff</i>	
From Targets to Targeted Therapies in Hepatocellular Carcinoma	145
<i>M. Cervello, M.R. Emma, G. Augello, D. Balasus, A. Azzolina, J.A. McCubrey, & A. Cusimano</i>	
Druggable Targets in Pancreatic Adenocarcinoma	195
<i>S. Nobili, R. Tassi, I. Landini, G. Perrone, C. Napoli, & E. Mini</i>	
Mechanisms of Raf-1 Kinase Inhibitor Protein Dysregulation in Triple-Negative Breast Cancers and Identification of Possible Novel Therapeutic Approaches for These Tumors	215
<i>N. D'Alessandro, P. Poma, M. Labbozzetta, N. Vivona, & M. Notarbartolo</i>	
Targeting PGE2 Signaling in Tumor Progression and Angiogenesis	223
<i>S. Donnini, F. Finetti, E. Terzuoli, L. Bazzani, & M. Ziche</i>	
Targeting Integrins in Cancer	233
<i>C. Pazzagli & S. Donnini</i>	

Forum on

Immunopathological Diseases and Therapeutics

VOLUME 5 AUTHOR INDEX

PAGE RANGE OF ISSUES: Issues 1-2: 1-114; Issues 3-4: 115-241

Achkova, D., 47	McCubrey, J.A., 145
Augello, G., 145	Mini, E., 195
Azzolina, A., 145	Montalto, G., 115
Balalus, D., 145	Multhoff, G., 137
Bazzani, L., 223	Napoli, C., 195
Blot, V., 25	Neri, D., 83
Cervello, M., 145	Newman, R., 1
Cleary, K.L.S., 7	Nobili, S., 195
Coronella, J., 25	Notarbartolo, M., 215
Cragg, M.S., 7	Oldham, R.J., 7
Cusimano, A., 145	Pazzagli, C., 233
D'Alessandro, N., 215	Perrone, G., 195
Donnini, S., 223, 233	Poma, P., 215
Emma, M.R., 145	Probst, P., 83
Finetti, F., 223	Richardson, R., 25
Giannitrapani, L., 115, 137	Sathish, J.G., 69
Grabulovski, D., 101	Soresi, M., 115
Granà, W., 115	Tassi, R., 195
Labbozzetta, M., 215	Terzuoli, E., 223
Landini, I., 195	Vivona, N., 215
Licata, A., 115	Wuellner, U., 101
Maher, J., 47	Ziche, M., 223

Forum on

Immunopathological Diseases and Therapeutics

VOLUME 5 SUBJECT INDEX

PAGE RANGE OF ISSUES: Issues 1-2: 1-114; Issues 3-4: 115-241

- adoptive immunotherapy, 47
Angiogenesis, 223, 233
antibodies, 1, 69
antibody-dependent cellular cytotoxicity (ADCC), 7
antibody-dependent cellular phagocytosis (ADCP), 7
antibody drug conjugate (ADC), 25
auristatin, 25
cancer, 1, 47, 83
cancer cells, 233
cancer therapy, 69
chimeric antigen receptor, 47
checkpoint activators, 69
checkpoint inhibitors, 69
conjugation, 25
cytokines, 83
cytotoxic T-lymphocyte-associated protein-4; (CTLA-4), 69
diagnosis, 115, 137, 145
drug resistance, 233
epidemiology, 115
epigenetic therapy, 215
Fc gamma receptor (FcγR), 7
hallmarks, 195
Hepatocellular carcinoma (HCC), 115, 137
immunocytokines, 83
immunosuppression, 69
immunotherapy, 83, 195
inflammation, 223
Integrins, 233
leukemia, 47
linker, 25
liquid biopsy, 137
lymphoma, 7, 47
maytansine, 25
microsomal prostaglandin E synthase-1 (mPGES-1), 223
monoclonal antibodies, 83
NF-κB inhibition, 215
non-Hodgkin's lymphoma, 1
off-target toxicity, 25
oncology, 101
On-target toxicity, 25
Pancreatic ductal adenocarcinoma (PDAC), 195
programmed cell death-1 (PD-1), 69
prostaglandin E2 (PGE2), 223
protein engineering, 101
pyrrollobenzodiazepine, 25
Raf-1 kinase inhibitor protein, 215
receptor tyrosine kinases (RTK), 223
rituxan, 1, 7
rituximab, 1, 7
scaffold, 101
selection, 101
signal transduction inhibitors, 145
site-directed conjugation, 25
stemness, 233
stress-inducible member heat-shock protein 70; (Hsp70), 137
targeted therapy, 145, 195
toxin, 25
treatment, 115
triple-negative breast cancers, 215
tumor biomarker, 137